Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Mohammad JahanzebHuamao M LinYanyu WuPingkuan ZhangMagdaliz GorritzCatherine B McGuinessWei-Ti HuangKainan SunChi-Chang ChenD Ross CamidgePublished in: The oncologist (2022)
Brigatinib appears to be effective and well-tolerated in the real-world ALK+ NSCLC population in the US, showing benefit in patients after a next-generation ALK-TKI. Notably, dose reduction rates appeared markedly less than those seen in trials when most trial-related dose reductions were for asymptomatic laboratory abnormalities.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- epidermal growth factor receptor
- small cell lung cancer
- chronic kidney disease
- clinical trial
- prognostic factors
- tyrosine kinase
- peritoneal dialysis
- open label
- study protocol
- phase iii
- randomized controlled trial
- patient reported outcomes
- drug induced